Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 9Hyperandrogenism 4Neoplasms 3Inflammation 2Heart Failure 2Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Skin Diseases 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Sarcoma 1Retinitis 1Renal Insufficiency, Chronic 1Rare Diseases 1Pulmonary Arterial Hypertension 1Pneumonia 1Pain 1Obesity 1Neutropenia 1Migraine Disorders 1Metabolic Syndrome 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

Gemcitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3selpercatinib 2parathyroid hormone-related peptide (1-36) 2niraparib 2Ocoxin 2Musculoskeletal Manipulations 2Metformin 2Clomiphene 2Cisplatin 2repotrectinib 1relacorilant 1pralsetinib 1pembrolizumab 1napabucasin 1lutetium Lu 177 dotatate 1fluorodopa F 18 1copper dotatate CU-64 1anlotinib 1adrenosterone 1Ultrasonography 1Thalidomide 1Sunitinib 1Spironolactone 1Parathyroid Hormone-Related Protein 1Parathyroid Hormone 1Paclitaxel 1Octreotide 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endocrine System Diseases × Spironolactone × Clear all
NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡